Exo Iris
Pocket-sized AI ultrasound that replaces carts and probes for faster scans, simpler workflows, confident care
Company profile
Company profile
Exo Inc is a medical imaging technology company pioneering an AI-powered point-of-care ultrasound (POCUS) platform that makes whole-body ultrasound accessible across healthcare settings. The company's flagship product, Exo Iris, is a pocket-sized, three-in-one handheld ultrasound device built on proprietary Piezoelectric Micromachined Ultrasonic Transducer (pMUT) silicon chip technology. This breakthrough approach combines the imaging excellence of piezoelectric crystals with the affordability and scalability of silicon manufacturing, featuring 4096 individual pMUTs that deliver ultra-high dynamic range imaging. Exo's comprehensive ecosystem includes SweepAI, an FDA-cleared real-time AI system that automatically labels anatomy, captures optimal views, and provides instant measurements without requiring internet connectivity. The platform also features Exo U, an AI-powered scan tutor that guides clinicians through proper probe motion and anatomy identification, and Exo Works, a device-agnostic workflow software that streamlines documentation, quality assurance, billing, and team collaboration. The company delivers FDA-cleared AI insights across multiple clinical applications including cardiac assessment (automated ejection fraction, chamber sizing, strain analysis), lung pathology detection (B-lines, effusions, consolidations), fluid management (IVC collapsibility, bladder volume), and population health screening. Exo serves health systems, hospitals, critical care units, emergency departments, sports medicine, rheumatology, and medical education programs. The platform is designed to replace traditional ultrasound carts and multiple probes with a single integrated solution that combines high-performance imaging, real-time AI guidance, and simplified workflows to enable confident care delivery at the point of need.
Company description Exo Inc official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Embedded deployment with recorded integration context.
Recorded integration context: device-agnostic ultrasound machine connectivity, EHR systems, PACS (Picture Archiving and Communication System).
Company milestones
FDA clearance for pleural effusion and consolidation/atelectasis AI (June 2025); Samsung Medison strategic partnership with Omar Ishrak joining board (May 2025); FDA clearance for HFpEF and cardiotoxicity indicators (April 2025); FDA clearance for SweepAI with hemodynamics and hypertension AI (December 2024); Geisinger deployment across 6 institutes, 10 hospital campuses, 86 connected machines
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Pocket-sized AI ultrasound that replaces carts and probes for faster scans, simpler workflows, confident care
Piezoelectric Micromachined Ultrasonic Transducer chip technology for ultrasound imaging
AI coach that guides probe motion, reveals anatomy, and teaches as you scan
Mobile-first, cloud-based POCUS workflow solution for documentation, billing, and QA
Rapid deployment solution for POCUS programs in healthcare organizations
AI that auto-labels anatomy, auto-captures key views, and auto-measures precisely, even offline
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Scientific reports · Jun 7, 2023
Clinical validation
No linked records are currently available.
Regulatory
K243239 · 510k · Apr 24, 2025
Strain AI (SAI001)K242359 · 510k · Nov 20, 2024
AI Platform (AIP001)K232501 · 510k · Nov 17, 2023
Bladder AI (AIBV01)K230497 · 510k · Jun 22, 2023
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Geisinger Critical Care department
Geisinger MSK Sports Medicine department
Geisinger Rheumatology department
Wellstar MCG Health
Published validation study
Published validation study
Enterprise POCUS workflow implementation across multiple departments and campuses to improve ultrasound documentation, billing, and quality assurance
40% increase in completed ultrasound exam documentation in Critical Care; 50% reduction in documentation time in MSK Sports Medicine; 3x increase in monthly POCUS exams in Rheumatology; 86 ultrasound machines connected across 6 institutes and 10 hospital campuses
Implementation of Exo Works to accelerate patient care and streamline exam documentation, QA, regulatory compliance, and revenue capture
47% increase in revenue capture
Point-of-care ultrasound workflow solution implementation
Solved infrastructure challenges for effective POCUS deployment
Medical education and student training for point-of-care ultrasound
Reduced feedback time from over 1 hour to a few minutes for student ultrasound review
05 · Leadership
Leadership profiles and professional links from the current Company record.
Sandeep Akkaraju
CEO and Founder
Dornoosh Zonoobi
CEO of Medo (acquired by Exo)
Omar Ishrak
Board Member
06 · Company updates
Recent articles published on Exo Inc's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.